Solazyme, Inc. (NASDAQ: SZYM), a leading innovator in microalgae, announced today that they will be exhibiting at the International Baking Industry Exposition (IBIE) in Las Vegas October 6 th-9 th. The company intends to showcase its breakthrough lipid alternative, Whole Algal Flour, at the show. This revolutionary baking solution is designed to improve the nutrition profile of bakery applications without sacrificing taste, texture or functionality. Whole Algal Flour can replace eggs, butter, milk and other lipid ingredients, providing a unique solution for gluten-free, sweet and savory baking applications. Solazyme will be sampling delicious baked goods made with Whole Algal Flour at Booth 2971. “Solazyme’s Whole Algal Flour provides significant opportunities for the bakery industry to dramatically improve the nutritional profile of their products while delivering the sensory experience consumers demand,” said Jean-Marc Rotsaert, Chief Operating Officer, Solazyme. “We are excited to be showcasing this breakthrough lipid ingredient at IBIE and offering clean label, non-allergenic, natural solutions to this industry.” Whole Algal Flour is one product in Solazyme’s suite of microalgae food ingredients, which includes revolutionary whole food high lipid and high protein products as well as a complete food oils portfolio. To learn more about Solazyme’s innovative suite of microalgae ingredients, please visit the sales team at IBIE Booth #2971 or visit us at www.solazyme.com. About Solazyme, Inc. Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils and innovative microalgal food ingredients. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world's three existing sources — petroleum, plants and animal fats. Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: Solazyme’s commercialization plans for microalgae food ingredients and the performance and health benefits of Solazyme’s microalgae food ingredients. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies and products; and market acceptance of its products. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme. In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.